EP 3294273 A4 20181205 - ANTI-INTERLEUKIN ANTIBODY PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
Title (en)
ANTI-INTERLEUKIN ANTIBODY PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
Title (de)
ANTI-INTERLEUKIN-ANTIKÖRPERZUBEREITUNGEN ZUR FREISETZUNG IN EIN LUMEN DES DARMTRAKTES MIT EINER EINNEHMBAREN WIRKSTOFFFREISETZUNGSVORRICHTUNG
Title (fr)
PRÉPARATIONS D'ANTICORPS ANTI-INTERLEUKINES À ADMINISTRER DANS LA LUMIÈRE DU TRACTUS INTESTINAL AU MOYEN D'UN DISPOSITIF D'ADMINISTRATION PHARMACOLOGIQUE À AVALER
Publication
Application
Priority
- US 201562159134 P 20150508
- US 2016031548 W 20160509
Abstract (en)
[origin: WO2016183040A1] Embodiments of the invention provide swallowable devices, preparations and methods for delivering therapeutic agents within the GI tract such as neutralizing proteins (NP) particularly antibodies which neutralize interleukins. Many embodiments provide a swallowable device e.g., a capsule for delivering various agents into the intestinal wall (IW). Embodiments also provide agent preparations that are configured to be contained within the capsule, advanced from the capsule into the IW and degrade to release the agent into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW. Embodiments of the invention are particularly useful for the delivery of interleukin NP's (INP) for treatment of inflammatory conditions where such INP's are poorly absorbed, tolerated and/or degraded within the GI tract.
IPC 8 full level
A61K 9/20 (2006.01); A61F 13/00 (2006.01)
CPC (source: EP)
A61K 9/4808 (2013.01); A61K 9/4866 (2013.01); A61K 39/395 (2013.01); A61M 31/00 (2013.01); A61P 1/04 (2018.01); A61P 7/00 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); C07K 16/244 (2013.01); C07K 16/2866 (2013.01); C07K 16/40 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01)
Citation (search report)
- [XP] WO 2015176031 A2 20151119 - INCUBE LABS LLC [US], et al
- [XY] US 2012027775 A1 20120202 - WON CHEE-YOUB [US], et al
- [Y] WO 2014066468 A1 20140501 - MEDIMMUNE LLC [US]
- [Y] WO 2009063222 A2 20090522 - UCL BUSINESS PLC [GB], et al
- [Y] WO 2008031770 A2 20080320 - COSMO TECHNOLOGIES LTD [IE], et al
- [Y] LONNBERG ET AL: "Targeting of interleukin-17 in the treatment of psoriasis", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 1 September 2014 (2014-09-01), pages 251, XP055328086, DOI: 10.2147/CCID.S67534
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2016183040 A1 20161117; AU 2016261599 A1 20171123; AU 2016261599 B2 20210826; AU 2021269453 A1 20211216; CA 2984422 A1 20161117; CA 2984422 C 20231017; CN 107835682 A 20180323; EP 3294273 A1 20180321; EP 3294273 A4 20181205; JP 2018520995 A 20180802; JP 2021042239 A 20210318; JP 7185401 B2 20221207; JP 7232805 B2 20230303
DOCDB simple family (application)
US 2016031548 W 20160509; AU 2016261599 A 20160509; AU 2021269453 A 20211122; CA 2984422 A 20160509; CN 201680040187 A 20160509; EP 16793347 A 20160509; JP 2017557954 A 20160509; JP 2020196688 A 20201127